[go: up one dir, main page]

WO1998021320A3 - Tissue type plasminogen activator (t-pa) variants: compositions and methods of use - Google Patents

Tissue type plasminogen activator (t-pa) variants: compositions and methods of use Download PDF

Info

Publication number
WO1998021320A3
WO1998021320A3 PCT/US1997/020226 US9720226W WO9821320A3 WO 1998021320 A3 WO1998021320 A3 WO 1998021320A3 US 9720226 W US9720226 W US 9720226W WO 9821320 A3 WO9821320 A3 WO 9821320A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
compositions
methods
plasminogen activator
tissue type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/020226
Other languages
French (fr)
Other versions
WO1998021320A2 (en
WO1998021320A9 (en
Inventor
Edwin L Madison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to JP52266198A priority Critical patent/JP2001505765A/en
Priority to EP97952176A priority patent/EP0950095A2/en
Priority to CA002271697A priority patent/CA2271697C/en
Priority to US09/600,985 priority patent/US6706504B1/en
Priority to AU55850/98A priority patent/AU735519B2/en
Publication of WO1998021320A2 publication Critical patent/WO1998021320A2/en
Publication of WO1998021320A3 publication Critical patent/WO1998021320A3/en
Publication of WO1998021320A9 publication Critical patent/WO1998021320A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Variants of tissue plasminogen factor exhibit significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co-factors, marked resistance to inhibition by PAI-1, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.
PCT/US1997/020226 1996-11-12 1997-11-12 TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE Ceased WO1998021320A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP52266198A JP2001505765A (en) 1996-11-12 1997-11-12 Variants of tissue-type plasminogen activator (t-PA): compositions and methods of use
EP97952176A EP0950095A2 (en) 1996-11-12 1997-11-12 TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE
CA002271697A CA2271697C (en) 1996-11-12 1997-11-12 Tissue type plasminogen activator (t-pa) variants: compositions and methods of use
US09/600,985 US6706504B1 (en) 1996-11-12 1997-11-12 Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
AU55850/98A AU735519B2 (en) 1996-11-12 1997-11-12 Tissue type plasminogen activator (t-PA) variants: compositions and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3065596P 1996-11-12 1996-11-12
US60/030,655 1996-11-12

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/600,985 A-371-Of-International US6706504B1 (en) 1996-11-12 1997-11-12 Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
US09600985 A-371-Of-International 1997-11-12
US10/705,633 Division US6869778B2 (en) 1996-11-12 2003-11-10 Tissue type plasminogen activator (t-PA) variants: compositions and methods of use

Publications (3)

Publication Number Publication Date
WO1998021320A2 WO1998021320A2 (en) 1998-05-22
WO1998021320A3 true WO1998021320A3 (en) 1998-07-09
WO1998021320A9 WO1998021320A9 (en) 1998-08-27

Family

ID=21855292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/020226 Ceased WO1998021320A2 (en) 1996-11-12 1997-11-12 TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE

Country Status (6)

Country Link
EP (1) EP0950095A2 (en)
JP (1) JP2001505765A (en)
CN (1) CN1244894A (en)
AU (1) AU735519B2 (en)
CA (1) CA2271697C (en)
WO (1) WO1998021320A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8864398A (en) * 1997-08-13 1999-03-08 Boehringer Mannheim Gmbh Plasminogen activator with enhanced zymogenic power and reduced fibrin linking
WO2014116706A1 (en) * 2013-01-22 2014-07-31 University Of Tennessee Research Foundation Tissue plasminogen activator antibodies and methods of use thereof
CN114736948B (en) * 2022-06-10 2022-11-08 深圳市帝迈生物技术有限公司 Alpha 2-antifibrinolytic enzyme activity determination kit

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199574A2 (en) * 1985-04-22 1986-10-29 Genentech, Inc. Human tissue plasminogen activator mutants, methods and intermediates therefor, and compositions using such mutants
WO1990002798A1 (en) * 1988-09-02 1990-03-22 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199574A2 (en) * 1985-04-22 1986-10-29 Genentech, Inc. Human tissue plasminogen activator mutants, methods and intermediates therefor, and compositions using such mutants
WO1990002798A1 (en) * 1988-09-02 1990-03-22 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETERSEN L C ET AL: "QUENCHING OF THE AMIDOLYTIC ACTIVITY OF ONE-CHAIN TISSUE-TYPE PLASMINOGEN ACTIVATOR BY MUTATION OF LYSINE-416", BIOCHEMISTRY, vol. 29, no. 14, 1990, WASHINGTON US, pages 3451 - 3457, XP002053064 *
TACHIAS K ET AL: "Variants of tissue-type plasminogen activator which display substantially enhanced stimulation by fibrin", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 31, 4 August 1995 (1995-08-04), BALTIMORE US, pages 18319 - 18322, XP002063362 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon

Also Published As

Publication number Publication date
AU735519B2 (en) 2001-07-12
JP2001505765A (en) 2001-05-08
WO1998021320A2 (en) 1998-05-22
CA2271697C (en) 2007-10-23
CN1244894A (en) 2000-02-16
AU5585098A (en) 1998-06-03
CA2271697A1 (en) 1998-05-22
EP0950095A2 (en) 1999-10-20

Similar Documents

Publication Publication Date Title
PL352150A1 (en) Use of phthalazine derivatives
AU1453200A (en) Cyclic peptide ligands that target urokinase plasminogen activator receptor, their pharmaceutical compositions and use
CA2288948A1 (en) Modified arginine deiminase
EP0278696A3 (en) An arg-serpin human plasminogen activator inhibitor designated pai-2
AU677540B2 (en) High-strength line-pipe steel having low yield ratio and excellent low-temperature toughness
CA2295693A1 (en) Mutant .alpha.-amylase having introduced therein a disulfide bond
AU1926001A (en) Novel human protein kinases and protein kinase-like enzymes
AU1515295A (en) Inhibitors of urokinase plasminogen activator
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
UA70919C2 (en) Composition for treating and preventing arterial thrombosis based on selective inhibitors of factor xa alone or in combination with compounds possessing anti-platelet aggregation activity
HUP9800634A3 (en) P-amidino-benzylamide derivatives as thrombin inhibitors, intermediates and use thereof
UA66793C2 (en) Leptin as inhibitor of tumor growth
PL325824A1 (en) Thio-substituted peptides as inhibitors of metal proteinases and thf liberation
AU6806487A (en) Tissue plasminogen activator
AU7690498A (en) Cleavage of fibrin(ogen) and cross-linked fibrin by fibrinolytic matrix metalloproteinases
AU6379101A (en) Highly selective inhibitors of the urokinase plasminogen activator
WO1998021320A3 (en) Tissue type plasminogen activator (t-pa) variants: compositions and methods of use
WO2000063247A3 (en) Osteopontin-derived chemotactic and inhibitory agents and uses therefor
EP1825864A3 (en) Antithrombotic agents
AU3951995A (en) Urokinase plasminogen activator fragments
AU8184301A (en) Inhibitors for the blood-clotting factor xa
PL304290A1 (en) Bifunctional urokinase variants having fibrinolnolytic properties and of thrombosin inhibiting action
AU2001234544A1 (en) Novel human protein kinases and protein kinase-like enzymes
AU3630695A (en) Semi-synthetic lipopeptides, compositions containing said lipopeptides, and methods of use
AU628491B2 (en) Mutants of urinary plasminogen activator, their production and use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97181346.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2271697

Country of ref document: CA

Ref document number: 1998 522661

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 55850/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1997952176

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997952176

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09600985

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 55850/98

Country of ref document: AU